Kornimate/medical-research-clean huggingface dataset:
biomarkers in bone marrow samples from patients with acute promyelocytic leukemia

Conditions: Adult Acute Myeloid Leukemia; Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Promyelocytic Leukemia (M3); Childhood Acute Promyelocytic Leukemia (M3)

Summary: this research study is studying biomarkers in patients with acute promyelocytic leukemia. studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and about biomarkers related to cancer.

observational study model: case-only time perspective: retrospective biospecimen retention: samples with dna bioscpecimen description: bone marrow study population description: primary care clinic sampling method: non-probability sample primary objectives: i. to measure wt1 and vegf-1 expression in patients with acute promyelocytic leukemia. outline: this is a multicenter study. patient mrna samples from diagnosis are analyzed via quantitative pcr to measure wt1 and vegf-1 expression.

Eligibility criteria:
inclusion criteria: * diagnosis of acute promyelocytic leukemia \[t(15;17) translocation\] * not specified * not specified
a multicenter prospective clinical study of endoscopic foam sclerotherapy for internal hemorrhoids

Conditions: Grade/Stage I Hemorrhoids; Prolapsed Grade II Internal Haemorrhoid; Prolapsed Grade III Internal Haemorrhoid

Summary: "internal hemorrhoid" affects the quality of life due to hemorrhage and prolapse as a common and frequently-occurring disease. endoscopic sclerosing agent injection has replaced traditional surgery and become the most commonly used treatment method in developed countries. at present, how to reduce the side effects of sclerosing agent and accurately determine the injection site and depth has become a difficult clinical problem. the research group creatively put forward the theory of foam sclerosing agent to treat internal hemorrhoids in the early stage. with the aid of transparent cap, the visibility of surgical field of vision can be improved. the mini probe ultrasound (mps) is proposed to effectively evaluate the submucosal in


Eligibility criteria:
inclusion criteria: * people are willing to sign the informed consent form of this trial. * people(aged 18 to 70 years) with clinical symptoms such as bleedingprolapse and so on have been diagnosed with grade i, grade ii and grade iii internal hemorrhoids by colonic epdoscopy; * people can follow short-term (3 month) and long-term (12 month) visit plans; * describe symptoms objectively and actively complete the evaluation scale; * no allergic diseases and allergy to sclerosing drugs; * non-lactating and pregnant women: patients without pregnancy plan (including the men) in 1 month after the test; * did not participate in any drug trials (including this trial drug) within 3 months before the trial; * people with long-term use of anticoagulant drugs (such as aspirin, clopidogrel, etc.) need to be stopped for 5-7 day exclusion criteria: * people with severe insufficiency of heart, brain, lung and other organs, leading to inability to tolerate endoscopic treatment; * people with drug allergies or abnormal blood coagulation function; * people suffering from or combined with digestive tract diseases,such as the colon malignancyulcerative colitis or crohn's diseaseacute diarrheaacute thrombotic internal hemorrhoids with painanal fistulaanal fissurefecal incontinence * men with history of severe prostate hypertrop; * people with any reasons that the researchers believe can not be selected

Keywords: hemorrhoids
optimizing the treatment strategy for age-related macular degeneration

Conditions: Wet Macular Degeneration

Summary: the purpose of this study is to compare two different treatment protocols for wet macular degeneration; the new protocol called "observe and plan" against the current standard protocol "treat and extend". studies suggest that patients achieve equally good visual acuity with fewer controls and that they are more satisfied with the new protocol.

the purpose of the study is to test a new treatment protocol for wet macular degeneration, called "observe and plan", against today's standard protocol "treat and extend". studies suggest that the individual treatment interval can be achieved earlier with "observe-and-plan" and that a proportion of patients do not need more than 3 injections, ie the loading dose. the other advantages seem to be that patients achieve good visual acuity with fewer controls and are more satisfied with the new protocol, which will be beneficial to both patients and health care. to our knowledge, no randomized controlled trial has tested this before.

Eligibility criteria:
inclusion criteria: * diagnosed age-related macular degeneration according to criteria. * new diagnose of active cnv verified with octa or fa / icga. * bcva ≥ 20/200 measured with etdrs visual acuity chart * written informed consent exclusion criteria: * eyes formerly treated with anti-vegf, photodynamic therapy, radiation therapy, transpupillary thermotherapy or focal laser photocoagulation involving the macular area. * geographic atrophy and subretinal fibrosis affecting the patient's visual acuity. * any other ongoing eye disease that influences patient's visual acuity, such as glaucoma with central vision loss, proliferative diabetic retinopathy, diabetic macular edema or chronic uveitis.

Keywords: outcome assessment, health care
buddhist awareness training program and qigong psychosocial interventions for people with insomnia

Conditions: Insomnia; Randomised Controlled Trial

Summary: this study aims to compare the efficacy of the mahayana buddhist awareness training program (atp) with a qigong group in treating people with insomnia in hong kong. it also aims to investigate the underlying mechanisms, including changes in brain activity and heart rate variability during wakefulness, through which these two eastern mind body interventions improve sleep quality. it is expected that atp will be as efficacious as qigong in enhancing sleep quality. compared to the qigong intervention, the more mind-based atp will lead to more improvement in mental health and greater reductions in hyperarousal brain activity. compared to atp, the more body-based qigong will lead to greater improvement in physical health and heart rate variability.


Eligibility criteria:
inclusion criteria: * (1) being a resident of hong kong; * (2) age between 50 and 75 years old; * (3) possessing the ability to read and write in chinese; * (4) obtaining a pittsburgh sleep quality index (psqi) score \> 5 at baseline * (5) demonstrating willingness to provide informed consent and adherence to study protocol. exclusion criteria: * (1) beck depression inventory-ii suicidal ideation score \>= 2; * (2) current use of hypnotic medications or any prescription medications that may influence sleep; * (3) necessity to take such medications during the trial period; * (4) ongoing therapies or clinical trials for insomnia; * (5) intention to undergo such clinical interventions during the trial period; * (6) working in shifts; * (7) engagement in considerable mindfulness practices exceeding 15 minutes per day; * (8) regular participation in different forms of qigong, aerobics, yoga, tai chi, or martial arts practice at least once a week in the past six months; * (9) limited mobility or health conditions that hinder the performance of specific qigong movements; * (10) currently receiving psychological, psychiatric or counselling services at least once a month; * (11) having been diagnosed with schizophrenia or psychosis by a clinician; * (12) having an active metal implant, pacemaker, or defibrillator in the body that affects objective assessment; * (13) impaired skin integrity or allergies to electrode gel or adhesive at the wearable eeg device placement site; * (14) pregnancy

Keywords: mahayana buddhist awareness training program electroencephalography qigong hong kong
effect of propofol midazolam on cerebral oxygenation and metabolism during clipping of ruptured cerebral aneurysm

Conditions: Ruptured Cerebral Aneurysm

Summary: despite the theoretical benefits of i.v. agents, volatile agents remain popular. in a study comparing desflurane, isoflurane, and sevoflurane in a porcine model of intracranial hypertension, at equipotent doses and normocapnia, cerebral blood flow (cbf) and icp were least with sevoflurane. propofol is the most commonly used intravenous anesthetic. it has many theoretical advantages by reducing cerebral blood volume (cbv) and icp and preserving both autoregulation and vascular reactivity. neurosurgical patients anaesthetized with propofol were found to have lower icp and higher cpp than those anaesthetized with isoflurane or sevoflurane. the well known pharmacodynamic advantages of intravenous anesthetics may give this group of drugs superior cerebral effects when compared with inhalation anesthetics.

the aim of this study is to evaluate the cerebral hemodynamics and global cerebral oxygenation as well as the systemic hemodynamic changes using midazolam and propofol as total intravenous anesthetics (tiva) in comparison with sevoflurane anesthesia in clipping of ruptured cerebral aneurysm.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status iii or iv. exclusion criteria: * morbid obese patients. * severe or uncompensated cardiovascular diseases * severe or decompensated renal diseases * severe or decompensated hepatic diseases * severe or decompensated endocrinal diseases. * pregnancy * postpartum * lactating females * allergy to one of the agents used. * severely altered consciousness level. * sitting or prone position during surgery.
ih636 grape seed extract in treating hardening of breast tissue in women who have undergone radiation therapy for early breast cancer

Conditions: Breast Cancer; Radiation Fibrosis

Summary: rationale: ih636 grape seed extract may lessen hardening of breast tissue caused by radiation therapy and may help patients live more comfortably. purpose: randomized phase ii trial to study the effectiveness of ih636 grape seed extract in treating hardening of breast tissue in women who have undergone radiation therapy for early breast cancer.

objectives: * determine the efficacy of ih636 grape seed proanthocyanidin extract for the treatment of radiation-induced fibrosis after high-dose radiotherapy in women with a history of early breast cancer. outline: this is a randomized, double-blind, placebo-controlled study. patients are stratified according to time since prior radiotherapy. patients are randomized to 1 of 2 arms. * arm i: patients receive oral ih636 grape seed proanthocyanidin extract three times daily for 6 months. * arm ii: patients receive an oral placebo three times daily for 6 months. patients are followed at 6 months. projected accrual: a total of 72 patients (48 for arm i and 24 for arm ii) will be accrued for this study.

Eligibility criteria:
disease characteristics: * history of early breast cancer * t1-t3, n0-n1, m0 * no evidence of cancer recurrence * palpable breast induration due to prior radiotherapy * hormone receptor status: * not specified patient characteristics: age: * 18 and over sex: * female menopausal status: * not specified performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * not specified radiotherapy: * see disease characteristics * at least 2 years since prior radiotherapy surgery: * not specified other: * at least 3 months since prior dietary supplementation containing ih636 grape seed proanthocyanidin extract over 50 mg per day

Keywords: radiation fibrosis stage i breast cancer stage ii breast cancer stage iiia breast cancer
healthy outcomes of pregnancy education

Conditions: Environmental Tobacco Smoke Exposure; Depression; Partner Abuse; Tobacco Smoking

Summary: the purpose of this study is to determine if an integrated intervention addressing active smoking, environmental tobacco smoke exposure, depression and intimate partner violence, would improve pregnancy outcome among african american women.

this study recruited pregnant, english speaking women from the district of columbia who were african american or latina and had one or more of the following risk factors: active smoking, environmental tobacco smoke exposure, depression and intimate partner violence. women were randomized to receive either an integrated intervention or usual prenatal care. women randomized to the intervention arm received a cognitive behavioral intervention delivered during the prenatal period in four to eight sessions. up to two postpartum booster sessions were provided. sessions were delivered coincident with prenatal care visits. careful attention was paid to individualizing counseling to provide an integrated approach to each participant's multiple risk factors. the outcomes of interest were primarily behavior change with regard to the risk factors and secondarily to improved birth outcomes, specifically birthweight and gestation.

Eligibility criteria:
inclusion criteria: * african american or latina (by self report) * at least 18 years of age * english speaking * pregnant less than or equal to 28 weeks gestation * receiving prenatal care in the district of columbia * had one or more of the following risk factors: active smoking, environmental tobacco smoke exposure, depression and intimate partner violence exclusion criteria: * non-minority race (by self report) * younger than 18 years of age * non-english speaking * not pregnant or pregnant greater than 28 weeks gestation * receiving prenatal care outside the district of columbia * responded negatively to questions about risk factors * suicidal ideation

Keywords: pregnant women intervention studies african americans infant mortality environmental tobacco smoke pollution depression partner abuse tobacco smoke
optimize pediatric oct imaging

Conditions: Retinal Disease; Glaucoma; Optic Nerve Diseases

Summary: handheld optical coherence tomography (oct) has become an important imaging modality to evaluate the pediatric retina. the objective of this pilot study is to compare a new contact oct system (theia imaging) with an investigational noncontact oct system (duke biomedical engineering) to assess their ability to image the pediatric retina. the investigators hypothesize that the contact oct system is superior in imaging larger areas of the retina (larger field-of-view), while it has similar resolution to image the retina substructures (non-inferior image quality).

handheld optical coherence tomography (oct) has become an important imaging modality to evaluate the pediatric retina. the objective of this pilot study is to compare a new contact oct system (theia imaging) with an investigational noncontact oct system (duke biomedical engineering) to assess their ability to image the pediatric retina. the investigators plan to enroll 10 healthy adult volunteers and 20 pediatric patients in clinic or undergoing examination under anesthesia. this is an observational study. there are no known risks associated with handheld oct imaging and no adverse events identified imaging with our prior investigational imaging with the same system. there is a risk of corneal abrasion with the contact imaging system (theia imaging), however, this system is used in the setting of other contact imaging systems (such as retcam fundus photography). imaging data will be downloaded to a secure server for protocol image processing, segmentation, and analysis per protocol in the duke advanced research in sd/ssoct imaging (darsi) laboratory.

Eligibility criteria:
inclusion criteria: * group 1 - healthy adult volunteers * subject is able and willing to consent to study participation * subject is more than 18 years of age * healthy adult volunteers without known ocular issues other than refractive error * pregnancy reasonably excluded guide (preg) evaluation on women of childbearing potential * group 2 - pediatric participants * health care provider, knowledgeable of protocol, agrees that study personnel could contact the parent/legal guardian * parent/legal guardian is able and willing to consent to study participation * pediatric patient less than 18 years of age in duke eye center ophthalmology clinics or undergoing clinically-indicated examination under anesthesia at duke eye center exclusion criteria: * group 1 - healthy adult volunteers * students or employees under direct supervision of the investigators * subjects with prior problems with pupil dilation * pregnant woman if receiving dilating drops * group 2 - pediatric participants * parent/legal guardian unwilling or unable to provide consent * participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)

Keywords: optical coherence tomography (oct)
promus premier™ china post-approval study

Conditions: Coronary Artery Disease

Summary: to compile real-world clinical outcome data for the promus premiertm everolimus-eluting platinum chromium coronary stent system (promus premiertm stent system) in routine clinical practice in china.

each site will be allowed to enroll up to a maximum of 300 subjects. the scheduled follow up will occur at 30 days, 6 months, 12 months and then annually through 5 years post stent implant, for all enrolled subjects. follow-up will be conducted via telephone contact or clinic visit

Eligibility criteria:
inclusion criteria: * subject must be at least 18 years of age * subject understands and provides written informed consent * subject who is clinically indicated and will have an attempt of at least one promus premiertm stent or subject who is clinically indicated and was implanted with at least one promus premiertm stent * subject is willing to comply with all protocol-required follow-up evaluation exclusion criteria: * exclusion criteria are not required in the pe premiertm china post-approval study which is an "all comers" study.
study of su011248 (sunitinib) given in a continuous daily regimen in patients with advanced renal cell cancer

Conditions: Carcinoma, Renal Cell Metastasis

Summary: to evaluate the anti-tumor activity of su011248 (sunitinib) in cytokine-refractory metastatic renal cell carcinoma (rcc) when administered in a continuous treatment regimen


Eligibility criteria:
inclusion criteria: * histologically proven renal cell carcinoma with metastases. * evidence of unidimensionally measurable disease as per response evaluation criteria in solid tumors (recist). * failure of 1 prior cytokine-based therapy for metastatic disease. patients treated with ifn-á alone must have received ifn-á for at least 4 weeks. * eastern cooperative oncology group (ecog) performance status 0 or 1. * resolution of all acute toxic effects of prior therapy or surgical procedures to grade 1. * adequate organ function exclusion criteria: * prior treatment with any systemic therapy other than 1 cytokine-based therapy. * previous treatment on a su011248 (sunitinib) clinical trial. * major surgery, radiation therapy, or systemic therapy within 4 weeks of starting the study treatment. * diagnosis of any second malignancy within the last 3 years, except basal cell carcinoma, squamous cell skin cancer, or in situ carcinoma that has been adequately treated with no evidence of recurrent disease for 12 months. * history of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease on screening computed tomography (ct) or magnetic resonance imaging (mri) scan. * any of the following within the 12 months prior to starting the study treatment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, congestive heart failure, cerebrovascular accident or transient ischemic attack, or pulmonary embolism. * ongoing cardiac dysrhythmias of grade 2, atrial fibrillation of any grade, or qtc interval \>450 msec for males or \>470 msec for females. * hypertension that cannot be controlled by medications (\>150/100 mmhg despite optimal medical therapy). * ongoing treatment with therapeutic doses of coumadin (however, low dose coumadin up to 2 mg po daily for deep vein thrombosis prophylaxis is allowed). * known human immunodeficiency virus (hiv) infection.
exploratory study on the efficacy and safety of semaglutide for idiopathic intracranial hypertension treatment

Conditions: Idiopathic Intracranial Hypertension

Summary: this study aims to investigate the safety and efficacy of semaglutide in patients with idiopathic intracranial hypertension.

idiopathic intracranial hypertension (iih) is a condition characterized by elevated pressure within the skull for reasons that are not yet understood. this condition does not involve abnormalities in the cerebrospinal fluid or any structural brain damage. individuals with this condition commonly experience persistent headaches, and some may face the potential of irreversible vision loss, significantly impacting their psychological well-being and overall quality of life. at present, the efficacy of medications like acetazolamide and topiramate in managing iih is constrained by practical clinical constraints. recent studies have indicated that glucagon-like peptide-1 receptor agonists show promise as a potential treatment option for iih. semaglutide, as a long-acting glucagon-like peptide-1 formulation, has a half-life of up to 160 hours and only needs to be injected once a week. it is easy to administer and has good safety and tolerability. hence, the objective of this study is to investigate the effectiveness and safety of semaglutide in managing idiopathic intracranial hypertension, laying the groundwork for subsequent extensive, multicenter research endeavors.

Eligibility criteria:
inclusion criteria: * age range from 18 to 75 years old, both male and female. * confirmed definite iih with papilledema and lumbar opening pressure ≥25 cm cerebrospinal fluid according to friedmann diagnostic criteria. * voluntarily sign a written informed consent form. exclusion criteria: * pregnant or breastfeeding women. * currently using any hypoglycemic drugs, including glucagon like peptide-1 receptor agonists. * known to be allergic to the active ingredients or any excipients in semaglutide. * history or family history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasias (men1/men2). * diabetes, ketoacidosis, severe gastrointestinal diseases, pancreatitis, severe heart failure. * vision loss caused by other diseases, such as diabetes retinopathy, iritis, cataract, etc. * malignant iih with vision at risk necessitating surgical intervention. * unable to cooperate in completing imaging examinations. * history of bariatric surgery or cerebrospinal fluid diversion. * have used any drugs known to increase intracranial pressure within the past 3 months (including vitamin a, tetracycline drugs, lithium, etc). * have participated in other clinical trials within the past 3 months, or did not withdraw from other clinical trials at the time of signing the informed consent form. * other situations determined by the researcher that may pose a threat to the patients' life safety or may have an impact on the study.